Previous 10 | Next 10 |
It is crystal clear that clinical trials are the surest way to bring new drugs into the market. While most clinical trials are costly, nine out of ten drugs in clinical development are never approved. Most of these treatments fail in clinical trials due to a lack of the desired effect, and som...
When the coronavirus pandemic reached the U.S., the FDA reacted swiftly to come up with quick solutions. In a few weeks, emergency testing was already in place, and that was an opportunity to convert some of the machines to be used as ventilators. The pandemic has paved the way for some new ch...
Digital data collection has played major roles in several aspects of our lives, reduced waste and removed room for human error. For example, airlines today transfer most of the data collection function to their customers, and we are willing (and even happy) to use our mobile devices to provide...
According to forecasts, the demand within the self-injection devices market is anticipated to grow a great deal in the years to come. This increase can be attributed to a number of factors as the discussion below explores. Transferring Responsibility to Individuals Over the years, there ...
A University of Oxford spinout focusing on genomics will benefit from a seed round of $11.4 billion. It aims at improving cancer detection by measuring epigenetic changes to tumor DNA circulating in a patient’s blood. The oversubscribed seed funding round was pioneered by Oxford Science...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it was added to the Russell 3000(R) Index after the market closed on Friday, June 26, 2020 as part of the 2020 Russell U...
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it was added to the Russell 3000 ® Index after t...
Are These On Your List Of Penny Stocks Right Now? When you think about “frothy stocks” do penny stocks come to mind? This is a term you’ll likely come across in the stock market today. What does frothy refer to in stocks? These are market conditions that typically come b...
June 25, 2020 Palm Beach, FL –June 25, 2020 – The triple negative breast cancer (TNBC) treatment market to grow at stellar CAGR through 2026. A recent report from Cole Market Research has stated that the ongoing advancements in cancer research continue to lead to the...
Genprex (NASDAQ: GNPX ) announces that the United States Adopted Names (USAN) Council has approved the non-proprietary name quaratusugene ozeplasmid for GPX-001, formerly called Oncoprex immunogene therapy for non-small cell lung cancer. More news on: Genprex, Inc., Healthcare stocks new...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...